Novavax, Inc.

Entry

Nuvaxovid manufacturing tech transfer to Sanofi completion ($75M milestone) · Company milestone

Drug

Nuvaxovid

For

COVID-19

Stage

Commercial / partnership

When

H1 2027 · the company gave a window, not a day

Source note

Novavax Aug 6, 2026 Q2 release: manufacturing technology transfer to Sanofi expected to complete mid-2027, triggering a $75M milestone. 'mid-2027' mapped to 2027-H1 per convention (could slip into early H2).

Checked

Checked by a person when it was added

Verify it

• Source: ir.novavax.com ↗ — where this entry was taken from
• SEC filings (8-K) ↗ — press releases are attached to 8-K filings
• ClinicalTrials.gov ↗ — trials of this drug
• NVAX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Entry

Novavax C. difficile vaccine clinical entry as early as 2027 · Company milestone

Drug

C. difficile vaccine candidate

For

Clostridioides difficile infection

Stage

Preclinical / pre-IND

When

2027 · the company gave a window, not a day

Source note

Q2 2026 release: candidate advanced into pre-IND interactions with FDA and GMP manufacturing initiated, supporting potential clinical entry as early as 2027 (hedged 'as early as').

Checked

Checked by a person when it was added

Verify it

• Source: ir.novavax.com ↗ — where this entry was taken from
• SEC filings (8-K) ↗ — press releases are attached to 8-K filings
• ClinicalTrials.gov ↗ — trials of this drug
• NVAX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Entry

Nuvaxovid beat mNEXSPIKE on tolerability in Phase 4 head-to-head COMPARE · Clinical trial results (readout / topline data)

Drug

Nuvaxovid (NVX-CoV2705)

For

COVID-19 prevention

Stage

Phase 4 · a study of a drug that is already approved

When

Apr 18, 2026

Source note

Sanofi presented positive results from COMPARE, the first head-to-head randomized Phase 4 study comparing tolerability of Novavax's protein-based Nuvaxovid with Moderna's mNEXSPIKE. Nuvaxovid showed statistically significant lower systemic reactogenicity across all pre-specified endpoints; data were presented at ESCMID Global in Munich.

Checked

Checked by a person when it was added

Verify it

• Source: ir.novavax.com ↗ — where this entry was taken from
• SEC filings (8-K) ↗ — press releases are attached to 8-K filings
• ClinicalTrials.gov ↗ — trials of this drug
• NVAX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Entry

PREVENT-19 topline: ~90% overall efficacy · Clinical trial results (readout / topline data)

Drug

NVX-CoV2373 (Nuvaxovid)

For

COVID-19 prevention

Stage

Phase 3 · the last stage before a drug can be approved

When

Jun 14, 2021

Source note

Phase 3 US/Mexico trial of Novavax's protein-based COVID-19 vaccine.

Checked

Checked by a person when it was added

Verify it

• SEC filings (8-K) ↗ — press releases are attached to 8-K filings
• ClinicalTrials.gov ↗ — trials of this drug
• NVAX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page